Internal Reference Number: FOI_9160
Date Request Received: 13/01/2026 00:00:00
Date Request Replied To: 04/02/2026 00:00:00
This response was sent via: By Email
Request Summary: Diffuse Large B Cell Lymphoma (DLBCL)
Request Category: Private Individuals
| Question Number 1: I have a Freedom of Information request that I would like to raise. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? a. Of these patients, how many commenced treatment at your trust within the last 6 months? | |
| Answer To Question 1: 7 patients diagnosed and 7 patients commenced treatment. | |
| Question Number 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: • R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) • R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) • (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Axicabtagene ciloleucel • Tisagenlecleucel • Epcoritamab • Loncastuximab tesirine • Glofitamab • Any other SACT • Stem cell transplant or bone marrow transplant (autologous or allogeneic) | |
| Answer To Question 2: R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) <5 • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) <5 • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) <5 • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) <5 • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)0 • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)0 • R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)0 • (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)0 • R-GemOX (rituximab, gemcitabine and oxaliplatin)0 • Axicabtagene ciloleucel0 • Tisagenlecleucel0 • Epcoritamab0 • Loncastuximab tesirine<5 • Glofitamab0 • Any other SACT <5 • Stem cell transplant or bone marrow transplant (autologous or allogeneic) none at SFT | |
| Question Number 3: In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): • Axicabtagene ciloleucel (Yescarta) • Tisagenlecleucel • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Glofitamab • Any other treatments | |
| Answer To Question 3: Axicabtagene ciloleucel (Yescarta) 0 • Tisagenlecleucel 0 • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) 0 • R-GemOX (rituximab, gemcitabine and oxaliplatin)0 • Stem cell transplant or bone marrow transplant (autologous or allogeneic) none at SFT • Glofitamab 0 • Any other treatments <5 | |
| Question Number 4: In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)? | |
| Answer To Question 4: None | |
| Question Number 5: In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: • CAR-T Therapy (E.g. Axicabtagene ciloleucel) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Any other treatment | |
| Answer To Question 5: Zero | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
